Quest Diagnostics Non-GAAP EPS of $3.12 beats by $0.30, revenue of $3.04B beats by $70M
Seeking Alpha ·
Quest Diagnostics press release ( DGX ): Q2 Non-GAAP EPS of $3.12 beats by $0.30 . Revenue of $3.04B (+10.1% Y/Y) beats by $70M . FY26 net sales consensus of $11.85B, EPS consensus of $10.77 Full year 2026 revenues now expected to be between $11.95
AI 시장 분석
Quest Diagnostics (DGX) reported Q2 Non-GAAP EPS of $3.12, beating market estimates by $0.30, with revenue reaching $3.04 billion, a 10.1% increase year-over-year. This strong performance reflects expanding demand in the healthcare and diagnostic services sector, sending positive signals to the related market. Investors should consider stable access to the healthcare sector based on robust revenue growth and upwardly revised annual guidance.
상승 영향
- Biotechnology — Quest Diagnostics' strong Q2 earnings with an EPS of $3.12, revenue of $3.04 billion, and upwardly revised annual guidance indicate expanding demand across the entire healthcare sector.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 73% · Bearish (Short) 27%
377 participants
Related News
- Ladder Capital Non-GAAP EPS of $0.24
- Oak Valley Bancorp GAAP EPS of $0.61, revenue of $20.61M
- Heritage Financial Non-GAAP EPS of $0.57 beats by $0.03, revenue of $84.12M misses by $2.18M
- Stora Enso GAAP EPS of -€0.03, revenue of €2.42B
- Jet fuel headwinds clip American Airlines' profit; FY26 outlook weighs on airline sector
- Micron Gets Vote of Confidence From Musk
